Cardlytics (CDLX)

As of 30 September 2026, short interest in CDLX is 594,060 shares, down 36,879 shares over the last month. Over the last 48 readings it ranged from 594,060 shares (30 September 2026) to 9,062,394 shares (15 April 2026). The latest reading sits at the bottom of that range. At the reported average volume of 29K shares a day that is 20.8 days to cover.

<iframe src="https://xoomar.com/embed/stocks/cdlx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 9 October 2026, the short share of CDLX volume is 64.5%, up 29.4 points over the last five sessions. Over the last 30 readings it ranged from 15.3% (18 September 2026) to 74.8% (2 September 2026). The latest reading is 20.6 points above the 30-session average of 43.8%, on 48K shares reported.

As of 8 September 2026, the fails-to-deliver balance in CDLX is 278 shares, down 44 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (12 June 2026) to 8,135 shares (23 June 2026). The latest reading sits at the bottom of that range.

Insiders at CDLX reported 4 open-market sells worth $101K in the last 90 days and no open-market buys. Latest filing: Gupta Amit (Chief Executive Officer) on 2026-10-02.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

21 Form 144 notices on file for CDLX worth $667K at the prices reported; 4 in the last 90 days worth $101K. Latest: Gupta Amit filed on 2026-10-02 to sell 7,382 shares ($19K) from 2026-10-02.

2 of the 30 tracked managers held CDLX at their latest 13F, $211K in total at quarter-end prices. Citadel Advisors is the largest at $128K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 0 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-30) Cardlytics reported revenue of $36.9M, down 36.5% from the same quarter a year earlier, and net loss of $14.9M. In FY 2025 it generated $9.3M of operating cash flow. As of 2026-06-30, cash was $28.0M against $184.4M of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.